论文部分内容阅读
2006年2月2日,阿斯利康公司宣布FDA已经给予该公司开发的髓质型甲状腺癌治疗药物ZactimaTM (ZD6474)快速审批资格。2005年10月该药还获得了罕见药资格。其所针对的适应症为滤泡型、髓质型、未分化型以及局部复发或转移的乳突型甲状腺癌。Zactima是一种多靶点化合物,可抑制和肿瘤生长转移有关的多个因子,如上皮生长因子受体(EGFR)和RET(REarranged during Transfection)酪氨酸激酶,还可通过抑制血管内皮生长因子受体(VEGFR)酪氨酸激酶来抑制肿瘤血供。甲状腺癌在美国每年新发病例25,000,其中髓质型甲状腺癌占其中的2%～3%;欧洲每年新发病例约25,000,髓质型甲状腺癌约占5%～8%。对于这种罕见遗传性的进展期疾病目前可供选择的治疗方案少,
On February 2, 2006, AstraZeneca announced that the FDA has granted ZactimaTM (ZD6474), a drug for the treatment of medulloblastic thyroid cancer developed by the company, for rapid approval. In October 2005, the drug also received rare drug qualifications. The indications they were targeting were follicular, medulloblastic, undifferentiated, and locally recurrent or metastatic papillary thyroid cancer. Zactima is a multi-targeted compound that inhibits multiple factors involved in tumor growth and metastasis, epidermal growth factor receptor (EGFR) and RET (rearranged during Transfection) tyrosine kinases, but also by inhibiting vascular endothelial growth factors. Receptor (VEGFR) tyrosine kinases inhibit tumor blood supply. There are 25,000 new cases of thyroid cancer each year in the United States, of which medulla thyroid cancer accounts for 2% to 3%; in Europe, about 25,000 new cases occur each year, and medulla thyroid cancer accounts for about 5% to 8%. There are currently fewer treatment options available for this rare hereditary progressive disease,